today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with ...

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody ... "Our Phase 1 data for XmAb942 validate ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized ... least squares [LS] mean difference, -1.5 [95% CI, -2.4, -0.5]; P ...

Anti-AChR and anti-MuSK antibody-positive people make up more than 90% ... recently estimated that Imaavy will hit $1.2 billion in 2030 sales. J&J will have its work cut out carving itself a ...

or anti–muscle-specific kinase antibody positive (MuSK+). 1 The approval of the FcRn-blocking monoclonal antibody, which works by reducing immunoglobulin G (IgG), was supported by data from the ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 antibody Keytruda (pembrolizumab) in a Chinese PD-L1-positive non-small ...

These results provide reassurance to the families of children born to anti-Ro antibody positive mothers. A total of 321 surveys were completed, 91% by parents and 9% by patients themselves.

TURKU, FI / ACCESS Newswire / May 12, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - BEXMAB data highlights meaningful clinical benefit, with beneficial immunological and hematological impact in ...

Pathological results were compared to 75 abnormal muscle biopsies associated with acquired immune or inflammatory myopathy syndromes and 14 muscle biopsies from patients with myopathies associated ...

Previous studies indicated the role of type I interferons (IFNs) in the pathogenesis of anti-MDA5 antibody-positive DM [1]. Recently, a striking similarity of clinical features and serum cytokine ...